Belite Bio, Inc. ADR
BLTE
Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing oral therapies for degenerative retinal diseases and selected metabolic disorders. Its lead candidate, Tinlarebant, is being studied for eye conditions such as Stargardt disease type 1 and geographic atrophy, with an emphasis on preserving retinal health and slowing disease progression. The company also develops LBS-009, a preclinical oral therapy aimed at metabolic diseases including liver disorders, type 2 diabetes, and gout. Belite Bio, Inc. ADR operates in the biotechnology and pharmaceuticals sector, where it contributes to the advancement of targeted treatments for conditions with significant unmet medical needs. The company is based in San Diego, California, and focuses on drug discovery and development centered on small-molecule therapeutics.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$102M
▼ -114.7% YoY
Op. Margin
–
ROIC
-14.50%
▲ +12.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$37M
▼ -26.5% YoY
Op. Cash Flow (FY)
-$37M
▼ -26.4% YoY
Net Debt
-$492M
Net Cash Position
Cash & Equiv.
$492M
Continue Research
Peers
Biotechnology · Pick stocks to compare with BLTE
Held by ETFs
BLTE is in 7 US ETFs. The largest of them, with BLTE's weight in each:
SPDR Portfolio Emerging Markets ETFSPEM0.03%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
- APActivePassive International Equity ETFAPIE0.06%of the fund
SPDR S&P China ETFGXC0.11%of the fund
- EHEven Herd Long/Short ETFEHLS0.33%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.77%of the fund
Belite Bio, Inc. ADR (BLTE) in three numbers
Questions about Belite Bio, Inc. ADR
Is Belite Bio, Inc. ADR a high-quality business?
Belite Bio, Inc. ADR scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$492M, and its weakest is return on capital at -14.5%. The Quality tab shows every check against its target.
Does Belite Bio, Inc. ADR (BLTE) pay a dividend?
No. Belite Bio, Inc. ADR (BLTE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BLTE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.